M&A / Deals GSK ends dementia alliance with Alector after setbacks PharmaphorumGSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.NeuroscienceRead full story pharminent July 9, 2026 (Last updated: July 10, 2026) Pharmaphorum GSK’s alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results. Neuroscience Read full story Post navigation Previous: FDA freezes CRL trove as ‘radical transparency’ push hits speedbumpNext: AstraZeneca, Ionis drug fails big heart disease study in major setback Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
